Stacy Lawrence

Business journalist

[FierceBiotech @FierceBiotech]

Novo Nordisk kills oral insulin, rejigs R&D to address U.S. payers: https://t.co/yE8GLE1X4h $NVO @StacyALawrence

[FierceBiotech @FierceBiotech]

Ex-Moderna CSO resurfaces at PureTech after abrupt departure: https://t.co/85lG5h9hcu @StacyALawrence

[FierceBiotech @FierceBiotech]

Roche highlights I/O combos, as it drops solo development of vanucizumab: https://t.co/3MYaDYlIHv $RHHBY @StacyALawrence

[FierceBiotech @FierceBiotech]

J&J backs neuro startup BlackThorn in $40M Series A: https://t.co/Z9CjUXuLoZ $JNJ @StacyALawrence

[FierceBiotech @FierceBiotech]

Small cap Rigel drops on PhIII failure for lead fostamatinib: https://t.co/ATRxF0ia1W $RIGL @StacyALawrence

[FierceBiotech @FierceBiotech]

Novartis invests, partners with Y Combinator grad in lysosomal storage disorders: https://t.co/xYdAYurDgV $NVS @StacyALawrence

[FierceBiotech @FierceBiotech]

Celgene partners to develop ResearchKit app for observational study: https://t.co/7qkg8X4TYp $AAPL $CELG @StacyALawrence

[FierceBiotech @FierceBiotech]

J&J eyes immuno-oncology with 15 R&D assets: https://t.co/Cp9xpi4Xci @StacyALawrence $JNJ

[FierceBiotech @FierceBiotech]

AstraZeneca backs ADC in $105M to support 6 clinical oncology candidates: https://t.co/poBt6N3Znc $AZN @StacyALawrence

[FierceBiotech @FierceBiotech]

Medicines Co. up on expectations of a twice-yearly anti-PCSK9: https://t.co/EMIYULEUFQ $MDCO @StacyALawrence

[FierceBiotech @FierceBiotech]

Clovis reveals ovarian cancer data underlying upcoming FDA review: https://t.co/A86BgPevJq $CLVS @StacyALawrence

[FierceBiotech @FierceBiotech]

Merck, NewLink nab up to $76M BARDA contract to back Ebola vaccine: https://t.co/T4W00tpKjx $MRK $NLNK @StacyALawrence

[FierceBiotech @FierceBiotech]

A pair of biotech IPOs line up: Myovant and Ra Pharma: https://t.co/h6VTkOy8Hr by @StacyALawrence

[FierceBiotech @FierceBiotech]

Fidelity backs rare disease startup with $48M to get pivotal data: https://t.co/TvvgBPULiG via @StacyALawrence

[FierceBiotech @FierceBiotech]

Microcap BioLineRx in-licenses a second NASH candidate under Novartis deal - https://t.co/gH4nPXqQdl

[FierceBiotech @FierceBiotech]

Intrexon partners with a pair of its fund portfolio startups - https://t.co/tMkgnX3sk0

[FierceBiotech @FierceBiotech]

German next-gen checkpoint inhibitor startup reels in €40M: https://t.co/SvjTb1wocM @StacyALawrence

[FierceBiotech @FierceBiotech]

Investors go bargain shopping as Novan IPO prices low, climbs high: https://t.co/SALGir4nPC @StacyALawrence

[FierceBiotech @FierceBiotech]

Moderna to plough $110M into manufacturing build-out: https://t.co/kgXBHYINVi @StacyALawrence

[FierceBiotech @FierceBiotech]

J&J builds on Geron partnership despite ongoing setbacks: https://t.co/bH1NvwQEyT $JNJ $GERN @StacyALawrence